Prefer to watch?
Not a new field.
This page is a 9-minute read. The video traces the field from Friedenstein's 1968 paper to today's approved products, the Phase III failure that reset it, and how the cGMP era changed the cells themselves. Keep scrolling for the full version.
Mesenchymal stem cells were named in 1991. The cells themselves were described in 1968.
The history matters because the marketing doesn't reflect it. The cheap end of this market talks about MSC therapy as if it sprang from a 2015 Joe Rogan podcast. The actual field is much older, much more boring, and much more rigorous than the marketing suggests. Sixty years of work, four Nobel-adjacent labs, two decades of failed Phase III trials in the U.S., one approved product in Japan, two in Korea, three in the EU, and one in Canada.
This page is the field's actual story: compressed into five eras, fifteen landmark papers, a then-versus-now comparison of how the work has changed, and a list of the products that have made it through regulators somewhere. The point isn't to oversell what's possible; it's to put what we offer inside the right frame, so the question stops being "is this real?" and starts being "is the version you're getting real?"
57 years
First isolation 1968 (Friedenstein). Cells named "mesenchymal stem cells" 1991 (Caplan).
~10 worldwide
Approved by a national regulator for at least one indication. None in the U.S. for systemic IV use.
1,400+ completed
Across all phases on clinicaltrials.gov, as of late 2024. Approximate count, drifting upward.
Sixty years in five chapters.
The eras below aren't arbitrary: each marks a structural change in how the cells were defined, made, regulated, or used. The discipline began as cell biology, drifted into bone-marrow-transplant medicine, and only became a manufacturing-and-regulatory enterprise in the last fifteen years.
- 1968Friedenstein isolates fibroblast-like cells from guinea pig bone marrow.
- 1976Cells shown to form colonies (CFU-F), first quantifiable assay.
- 1988Owen & Friedenstein describe the marrow stromal cell.
- 1991Caplan coins "mesenchymal stem cell" at Case Western.
- 1995First human MSC trial, bone-marrow stromal cells, hematologic indication.
- 1999Pittenger paper shows tri-lineage differentiation in vitro.
- 2006ISCT publishes the minimal-criteria definition still in use.
- 2009Prochymal Phase III misses primary endpoint in steroid-refractory GvHD.
- 2012First MSC product approved in Canada (Prochymal, pediatric GvHD).
- 2015Temcell approved in Japan (PMDA conditional pathway).
- 2018Alofisel approved by EMA for perianal fistula in Crohn's.
- 2020cGMP standards for cell therapies harmonize across major regions.
- 2021Multiple national programs (KR, JP, CL) expand approvals.
- 2023Remestemcel-L receives U.S. FDA priority review (eventually approved 2024).
- NowApproved products in 6+ jurisdictions; U.S. systemic IV still trials-only.
Twelve papers that built the field.
You don't need to read all twelve. But you should know they exist. Most of the cheap end of this market acts as if MSC biology is settled science with strong clinical evidence in every indication. It isn't. It's a real field with real papers and real failures, and the failures matter as much as the successes, especially the 2009 Prochymal Phase III, which is the moment the discipline became serious about manufacturing variability.
What you should take from this list: this is a field where the regulatory wins of the 2010s came after the manufacturing wins. Cells were known; the problem was reproducibly making the same cells twice. The cGMP era is what fixed that, and it is the reason a 2025 infusion is structurally different from a 2005 one, even if the cell type on paper looks identical.
What's changed since the discovery era.
The most misleading thing about the cheap end of this market is that it implies the field is the same as it was in 2005: same cells, same technique, same evidence base. The discipline has changed under it. The table below is the easiest way to see how.
The products that exist, and where.
An "approved product" means a national regulator has reviewed the manufacturing, the clinical data, and the labeling, and authorized commercial sale for at least one indication. It is the highest bar in this discipline. The list is short. None of these products are what you receive at a clinic offering self-pay infusions, those operate under different regulatory frames, but they are the existence proof that MSC therapeutics can clear the highest gates.
Indication:Pediatric steroid-refractory acute graft-versus-host disease. Allogeneic bone-marrow-derived MSCs. The same product approved in CA (2012), JP (2015 as Temcell), and finally the U.S. (Dec 2024).
Indication:Complex perianal fistulas in Crohn's disease. Allogeneic adipose-derived MSCs, locally injected. First MSC product approved by EMA.
Indication:Cartilage defects in osteoarthritis of the knee. Allogeneic umbilical-cord-derived MSCs, surgically applied. First UC-derived MSC product approved anywhere.
Indication:Crohn's-related fistulas. Autologous adipose-derived MSCs. Domestic-only product.
Indication:Critical limb ischemia in Buerger's disease. Allogeneic bone-marrow-derived MSCs. Approved under India's CDSCO accelerated pathway.
Indication:Spinal-cord injury. Autologous bone-marrow-derived MSCs. Approved under Japan's conditional/time-limited pathway; under post-market surveillance.
What's missing from the list, and what matters: there is no approved MSC product anywhere in the world for IV infusion in osteoarthritis, autoimmune disease, anti-aging, or longevity. That is the market our program operates in. We are not pretending it's something else. The honest framing is that we are using a real, regulated, manufactured biological product, in a clinical context, for indications where the evidence is suggestive but not yet at the standard required for a commercial approval. That's true everywhere this kind of clinic exists, including ours.
Three things this page should reset.
What to take from the timeline.
- This isn't a new field. Friedenstein's first paper is 1968. The cheap end implies the discipline is fifteen years old. It is fifty-seven.
- The 2009 failure is the most important thing in the timeline. Prochymal's missed Phase III is what produced the cGMP-era seriousness about manufacturing variability. The discipline got better at making cells reproducibly because of that loss.
- Approval ≠ existence. An MSC infusion in an unapproved indication is not by itself illegitimate; it is a legitimate biological product being used at the edge of where it has been formally validated. The honest version of this market says that. The dishonest version implies the approval boundary doesn't exist.
Friedenstein 1968 → Caplan 1991 → Prochymal 2012 → Ryoncil 2024. That's the field.
Five eras, twelve landmark papers, six approved products in six jurisdictions, one Phase-III failure that mattered more than most of the wins, and a manufacturing discipline that has changed under the marketing. What you receive at any clinic in this market is rooted in this history, and how a clinic talks about that history tells you which version of it they are operating in.